PEAK6 LLC acquired a new stake in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 199,995 shares of the company's stock, valued at approximately $586,000. PEAK6 LLC owned about 0.07% of AbCellera Biologics at the end of the most recent quarter.
Several other large investors have also recently modified their holdings of ABCL. State Street Corp grew its position in AbCellera Biologics by 1.5% during the 3rd quarter. State Street Corp now owns 323,229 shares of the company's stock worth $840,000 after acquiring an additional 4,679 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of AbCellera Biologics by 10.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 62,629 shares of the company's stock worth $184,000 after purchasing an additional 5,955 shares during the last quarter. DKM Wealth Management Inc. purchased a new position in shares of AbCellera Biologics in the fourth quarter worth $29,000. State of New Jersey Common Pension Fund D purchased a new stake in AbCellera Biologics during the 4th quarter valued at $36,000. Finally, B. Riley Wealth Advisors Inc. boosted its position in AbCellera Biologics by 58.1% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 34,000 shares of the company's stock valued at $88,000 after buying an additional 12,500 shares during the period. Hedge funds and other institutional investors own 61.42% of the company's stock.
AbCellera Biologics Stock Performance
Shares of NASDAQ ABCL traded down $0.03 during midday trading on Friday, hitting $2.57. 2,976,557 shares of the company traded hands, compared to its average volume of 2,662,108. AbCellera Biologics Inc. has a 12-month low of $1.89 and a 12-month high of $4.34. The firm has a market cap of $765.83 million, a P/E ratio of -4.21 and a beta of 0.50. The stock has a 50-day moving average price of $2.44 and a 200 day moving average price of $2.77.
Wall Street Analysts Forecast Growth
ABCL has been the subject of a number of analyst reports. Stifel Nicolaus dropped their target price on shares of AbCellera Biologics from $12.00 to $10.00 and set a "buy" rating for the company in a report on Friday, February 28th. Benchmark reiterated a "hold" rating on shares of AbCellera Biologics in a research report on Monday, March 3rd. Finally, KeyCorp upped their target price on AbCellera Biologics from $4.00 to $5.00 and gave the company an "overweight" rating in a report on Wednesday, April 16th.
Check Out Our Latest Research Report on ABCL
About AbCellera Biologics
(
Free Report)
AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
See Also
Before you consider AbCellera Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbCellera Biologics wasn't on the list.
While AbCellera Biologics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
